
The addition of the investigational PI3K inhibitor pictilisib to the aromatase inhibitor Faslodex in patients with metastatic breast cancer yielded some intriguing findings in the FERGI study.

The addition of the investigational PI3K inhibitor pictilisib to the aromatase inhibitor Faslodex in patients with metastatic breast cancer yielded some intriguing findings in the FERGI study.